|
Session 1
The Clinical and Research Challenges of Scleroderma
Chairs – Daniel Furst and Jaap van Laar |
|
09:00 |
Translational biology and new therapies |
JOHN VARGA |
|
09:35 |
Epigenetic modifications in SSc |
BASHAR KAHALEH |
|
10:10 |
Discussion |
|
|
10:30 |
COFFEE BREAK |
|
|
Session 2
Immunology: Innate Immunity
Chairs – Robert Lafyatis and Hans Stauss |
|
11:00 |
Immune aspects of dendritic cells |
TIMOTHY RADSTAKE |
|
11:25 |
Apoptosis and the immune response |
KEITH ELKON |
|
11:50 |
Molecular diversity of the IFN pathway |
PEGGY CROW |
|
12:15 |
Discussion |
|
|
12:30 |
LUNCH |
|
|
Session 3
Infection and Environmental Triggers
Chairs – Armando Gabrielli and Arnold Postlethwaite |
|
1:30 |
Infections and autoimmunity |
IRUN COHEN |
|
1:55 |
Infectious diseases, innate immunity and fibrosis |
CORY HOGABOAM |
|
2:20 |
Nephrogenic Systemic Fibrosis as a scleroderma model |
SERGIO JIMENEZ |
|
2:45 |
Discussion |
|
|
3:00 |
TEA BREAK |
|
|
Session 5
Inflammation and Mesenchymal Stroma
Chairs – Kristofer Rubin and Maria Trojanowska |
|
09:00 |
Effects of matrix density on cellular phenotype (not only in
carcinoma) |
VALERIE WEAVER |
|
09:25 |
Regulation of Extracellular Matrix Production by Hypoxia:
Implications for Cancer and Fibrosis |
AMATO GIACCIA |
|
09:50 |
Stromal reactions in carcinoma and its similarity and
differences to tissue fibrosis |
MIKE OSTROWSKI |
|
10:15 |
LOXL2 in pathologic fibrotic microenvironment |
VICTORIA SMITH |
|
10:40 |
Discussion |
|
|
10:50 |
COFFEE BREAK |
|
|
Session 6
What causes Scleroderma? General Round Table Discussion
Session
Chairs – Bashar Kahaleh, Maureen Mayes, Neil McHugh, Arnold
Postlethwaite,
Timothy Radstake, Douglas Veale, Ken Welsh |
|
11:20 |
Introduction and Round Table Discussion |
|
|
12:45 |
LUNCH |
|
|
Session 7
Genomics and Post-Genomics
Chairs – John Varga and Michael Whitfield |
|
1:45 |
Methylation determines fibroblast activation and fibrogenesis
in the kidney |
MICHAEL ZEISBERG |
|
2:10 |
Transcriptional analysis of models –– Comparative
analysis |
MICHAEL WHITFIELD |
|
2:35 |
Genetic of complex autoimmune diseases |
JAVIER MARTIN |
|
3:00 |
Discussion |
|
|
3:15 |
TEA BREAK |
|
|
Session 8
Novel Regulatory Pathways in Fibrosis
Chairs – Humphrey Gardner and Marco Matucci Cerinic |
|
3:45 |
Sphingosine 1 phosphate in health and disease |
NIGEL PYNE |
|
4:10 |
Non canonical WNT signalling in fibrosis and angiogenesis |
FRANCESCO DEL GALDO |
|
4:35 |
Epithelial cells promote dermal fibroblast activation via
IL-1α
in systemic sclerosis |
RICHARD STRATTON |
|
5:00 |
Discussion |
|
|
5:15 |
END OF SESSION |
|
|
7:30 |
BANQUET SPEAKER: SIR GREGORY WINTER |
|
|
Session 9
The Fibrillin Area and Fibrosis
Chairs – Thomas Krieg and Kristofer Rubin |
|
09:00 |
Fibrillins: Key extracellular determinants of tissue
formation and fibrosis |
FRANCESCO RAMIREZ |
|
09:25 |
Mechanisms of TGF-b activation |
DAN RIFKIN |
|
09:50 |
Fibrillin related diseases |
ELIZABETH GERBER |
|
10:15 |
Discussion |
|
|
10:30 |
COFFEE BREAK |
|
|
Session 10 - Models Systems (In vitro and in vivo approaches)
Chairs – James Tomasek and Robert Lafyatis |
|
11:00 |
Fibroblast biomechanical cues as key regulators of matrix
remodelling |
BORIS HINZ |
|
11:25 |
Targeting fibroblasts in vivo |
ANDREW LEASK |
|
11:50 |
Chemical induced models – strengths and weaknesses |
OLIVER DISTLER |
|
12:15 |
Discussion |
|
|
12:30 |
LUNCH |
|
|
Session 11 - Biomarkers and Disease Classification/New
Technology Areas
Chairs – Luc Mouthon and Philip Clements |
|
1:30 |
The Resolution of Inflammation: Players and Targets |
MAURO PERETTI |
|
1:55 |
Contribution of proteomics to the identification of
biomarkers in vascular diseases |
LUC MOUTHON |
|
2:20 |
Identification of biomarkers in systemic sclerosis |
ROBERT LAFYATIS |
|
2:45 |
Composite measures of disease outcome – lessons from PF-SSc |
LESLEY ANN SAKETKOO |
|
3:10 |
Discussion |
|
|
3:30 |
END OF SESSION |
|
|
|
AFTERNOON TEA |
|
|
Session 12
Vascular Pathology and Remodelling in PAH
Chairs – Lucie Clapp and Clive Handler |
|
09:00 |
Future therapy of pulmonary arterial hypertension: reversing
advanced disease |
RUBIN TUDER |
|
09:25 |
Molecular mechanism of the TNF superfamily in PAH |
ALLAN LAWRIE |
|
09:50 |
The role of TGFbeta in heritable PAH |
ALAN HOLMES |
|
10:15 |
Oestrogen and the serotonin system in the development of PAH |
MARGARET MACLEAN |
|
10:40 |
Discussion |
|
|
11:00 |
COFFEE BREAK |
|
|
Session 13
Applying Cell Biology to Human Disease
Chairs – Christopher Denton and Ariane Herrick |
|
11:30 |
Biomarkers of cancer risk and molecular targets for early
Intervention |
JILL SIEGFRIED |
|
11:55 |
Therapeutic opportunities offered by reversible
ubiquitination |
MICHAEL CLAGUE |
|
12:20 |
Discussion |
|
|
12:30-12:40 |
Future perspectives for the 2013 Workshop |
CAROL BLACK & ROBERT LAFYATIS |
|
12:40 |
LUNCH |
|
|
Session 14
Scleroderma Clinical Trials Consortium
Chair – Peter Merkel |
|
1:00 |
Update on the EULAR Points to Consider Project |
DINESH KHANNA |
|
1:15 |
Update on the ACR-EULAR Scleroderma Classification Project |
DINESH KHANNA |
|
Interactive Session – Clinical trial design in scleroderma:
Where do we go next? |
|
1:30 |
Introduction |
PETER MERKEL |
|
1:40 |
Discussion- Primary outcome for clinical trials: Skin vs.
lung vs. composite |
CHRIS DENTON, Leader |
|
2:00 |
Discussion-Digital ulcers in scleroderma: Healing vs. repair
vs. composite |
LORI CHUNG, Leader |
|
2:20 |
Discussion-Pulmonary arterial hypertension in scleroderma |
OLIVER DISTLER, Leader |
|
3:00 |
Discussion-Relatively unstudied aspects of scleroderma:
Opportunities for study or of lower priority and feasibility? |
DANIEL FURST, Leader |
|
3:20 |
Discussion-Summary and wrap up: What are the priorities? |
PETER MERKEL, Leader |
|
|
END OF WORKSHOP |
|
